ليتروزول تيڤع

Country: Իսրայել

language: արաբերեն

source: Ministry of Health

active_ingredient:

LETROZOLE 2.5 MG

MAH:

TEVA PHARMACEUTICAL INDUST.LTD

ATC_code:

L02BG04

pharmaceutical_form:

TABLETS

administration_route:

PER OS

manufactured_by:

TEVA PHARMACEUTICAL INDUSTRIES LTD

therapeutic_group:

LETROZOLE

therapeutic_indication:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

authorization_date:

2010-01-01